News | February 24, 2021
USFDA denies Sun Pharma Advanced Research’s appeal of NDA for Taclantis
The company will review FDA's response and decide on appropriate next steps soon.
The company will review FDA's response and decide on appropriate next steps soon.
Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .
Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness
Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).
posaconazole delayed-release tablets 100 mg are the generic equivalent of Noxafil.
The centralized marketing authorization granted by the EC is valid in all EU Member
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
The partnership is a significant step in delivering advanced cancer therapies to patients.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Subscribe To Our Newsletter & Stay Updated
